Terumo shares slide after first-half results and guidance cut
Terumo shares dropped 6.2% to ¥2,399.5 on Friday, following first-half fiscal 2026 results released the previous evening that combined record adjusted profit with a sharp fall in reported earnings and a significant cut to full-year guidance.
For the six months ended September 30, 2026, reported operating profit fell 30% to ¥70.8 billion, dragged down by ¥76.4 billion in impairment losses and charges tied mainly to ending the CSL Plasma supply agreement. Terumo also reduced full-year operating profit guidance by ¥41 billion to ¥119 billion and lowered its net profit forecast to ¥87.5 billion from ¥120 billion, a cut of about 27%.
In a further setback, Terumo said a voluntary recall and shipment suspension at its Terumo Aortic unit is expected to trim full-year revenue by about ¥8 billion and operating profit by ¥41 billion, including an estimated ¥38 billion of risks related to Aortic asset values that have not yet been fully determined.
The selloff came despite a generally supportive backdrop for Japanese equities, with the Nikkei 225 gaining as much as 1.5% as it rebounded from losses through October and early November.
This article was produced with AI assistance and reviewed by an editor. For more information, see our terms and conditions.